IFF Opens New Dubai Taste Creative Center
IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition & ingredients, today announced the opening of a new creation, application and innovation center for its Taste division in Dubai, UAE to better serve its customers’ unique needs and drive growth in the African, Middle Eastern, Turkish and Indian markets.
“The new facility is a testament to our commitment to investing in the region and to support the specific innovation needs of our customers, leveraging dedicated leadership and cross-functional regional resources,” said Kathy Fortmann, Divisional CEO, Taste. “It will support our ongoing strategy to expand our geographic and customer reach, while accelerating growth in fast-growing emerging markets.”
The state-of-the-art 1400m2 creative facility, centrally located in Dubai Science Park, will service companies in key regional markets by offering innovative flavors, savory solutions, juice-based compounds, inclusions, colors, and food protection solutions. The new lab will support both the creation and application needs of all key categories, including snacks, beverages, savory, sweet, and dairy. The site also includes a full-scale Sensory and Consumer Insights lab, as well as an analytical lab. In line with the Company’s focus on sustainability, the facility is LEED certified.
Helga Moelschl, Vice President, Regional General Manager, added, “With our investment in the Dubai Creative Center, we are reaching a key milestone to provide enhanced and locally relevant support for our regional customer base through strong consumer insights, deep understanding of the consumer in these exciting markets, and speed-to-market. Our customers will also gain access to our global Re-Imagine innovation programs, which will bring global capabilities to the local markets. We are committed to raising the bar on the products and services we provide to meet our customers’ needs – both for now and in the future.”
IFF has a long-standing presence and footprint in key Middle East markets. The investment follows the 2017 expansion and upgrade of the Taste facility in Cairo, Egypt, which has been operational since 1979 and includes sales offices, creation and applications labs and flavor production facilities. It is also the second investment made specifically in Dubai, where in 2011, IFF opened a state-of-the-art flavor and fragrance facility, housing creative and application labs and sales and marketing offices.
Welcome to IFF
At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn.
Head of Investor Relations and Communications
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 20201.12.2020 18:01:00 EET | Press release
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients. Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid-19 viral replication. RP7214 has also been studied extensively across multiple inflammation models where it has demonstrated excellent anti-inflammatory activity
Andersen Global Adds Collaborating Firm in Azerbaijan1.12.2020 17:30:00 EET | Press release
Andersen Global expands into Azerbaijan by way of a Collaboration Agreement with independent Baku-based law firm MGB Law Offices, adding coverage and positioning the organization for further expansion between Europe and Asia. Founded in 1995, MGB Law Offices, which has ten lawyers, has been recognized by IFLR1000, Legal500 and Chambers and Partners as the leading law firm in Azerbaijan. Led by Managing Partner Ismail Askerov, the full-service firm offers solutions in various industries such as oil and gas, aviation, banking and finance, insolvency and restructuring, tax, privatization law and foreign investment. The firm’s client base includes blue-chip multinationals, international financial institutions, insurance companies, airlines, telecom companies and other business entities. “We are proud of our ability to consistently deliver best-in-class services, and our comprehensive solutions position us to be one of the most reputable law firms in the market by allowing us to meet the di
Alira Health Achieves AWS Select Consulting Partner Status1.12.2020 17:00:00 EET | Press release
Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, announced it has recently earned Amazon Web Services (AWS) Select Consulting Partner status. The firm’s newly formed Advanced Analytics practice will leverage AWS’s cloud computing capabilities to provide greater value to clients, providing fully compliant, made-to-measure digital solutions, powered by AWS, that securely enable the use of data generated by the healthcare community and clients’ own internal data. The solutions are provided to customers in the form of Software-as-a-Service (SaaS), seamlessly integrating into existing workflows and designed to support clients in prioritizing research and development (R&D) investments, identifying novel therapeutic areas suitable for corporate business development, and assessing business opportunities. “Technology has the power to solve complex problems and be a transformative tool across the healthcare and life sciences ecosystem,” said
Rimini Street Awarded Three Brazilian Public Sector Contracts to Support Oracle and SAP Enterprise Software Systems1.12.2020 17:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that it has been awarded three separate contracts to provide enterprise software support to agencies linked to the Legislative, Executive and Judiciary branches of the Brazilian government, specifically the Chamber of Deputies, the Superior Labor Court and APEX Brasil, an independent social service agency. The Brazilian government public procurement processes were put in place to ensure that public sector organizations work with providers in a manner that is transparent, efficient, ensures economy of scales and the best optimization of public resources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201005501/en/ Rimini Street Awarded Three Brazilian Public Sector Contracts to Support Oracle and SAP Enterp
Market Access Transformation (MAT) Secures First Institutional Funding Led by Silversmith Capital Partners1.12.2020 17:00:00 EET | Press release
Market Access Transformation (MAT), a global healthcare company that uses cutting edge technology to automate and modernize how life sciences companies capture mission-critical insights that drive decision-making across the product lifecycle, today announced a $30 million minority investment from Silversmith Capital Partners, a Boston-based growth equity firm. The investment marks the first time MAT has raised outside capital and will be used to expand the company’s team and accelerate innovation of its product offerings. Founded in 2016, MAT has revolutionized the way Global Payer Market Research is conducted by developing Rapid Payer Response (RPR), the industry’s only on-demand global platform for gathering critical payer insights. In five years, the company has built a client base of more than 45 biopharma and device manufacturers – including all of the Top 10 pharma companies. MAT’s partnership with Silversmith solidifies its market leadership position in providing technology-driv
PCI Pharma Services Announces the Closing of the Majority Stake Acquisition by Kohlberg and Mubadala1.12.2020 17:00:00 EET | Press release
PCI Pharma Services (“PCI” or “the Company”), a leading pharmaceutical and biopharmaceutical global supply-chain solutions provider, today announced the closing of the previously announced acquisition that gives Kohlberg & Company, LLC (“Kohlberg”) a majority stake in the company. Mubadala Investment Company and Partners Group (acting on behalf of its clients) will have minority shares in the Company. This milestone is a key step for PCI, as Kohlberg and Mubadala will be partnering with PCI’s management team, led by CEO Salim Haffar, to continue the Company’s transformation journey. The team will be adding specific capabilities and geographies organically and inorganically to improve PCI’s client experience and enable its clients to bring life-changing biopharmaceutical therapies to market. Leveraging the global growth trends in biologics and specialized drug therapies, future capabilities include sterile fill finish of injectables, expanding high potency and specialized manufacturing,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom